elacestrant tablets,
For oral use Initial U.S. Approval: 2023

As specified in the prescribing information, Orserdu (elacestrant) is indicated for the treatment of breast cancer disease. As per highlights Of prescribing information (elacestrant) tablets is an estrogen receptor antagonist indicated for: • treatment of postmenopausal women or adult men, with ERpositive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

Facts about elacestrant tablets

Disease Indications: Breast Cancer
Dosage Forms And Strengths: Tablets: 345 mg and 86 mg
Manufacturer: Stemline Therapeutics
Usage: Oral
Medicine Approved By: Food and Drug Administration (FDA)
Orserdu (elacestrant) was approved by the FDA in January 2023

Extra Information:

• Full prescribing information [FDA]: Orserdu (elacestrant) [PDF] Stemline Therapeutics, Inc., January 2023.
• FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer FDA, January 2023

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “elacestrant tablets” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.